SUMMARY A randomised controlled trial of thymic hormone extracts (Thymostimulin) (1 mg/kg/day for seven days; 1 mg/kg/weekly thereafter) was undertaken in 30 patients (21 women, nine men) with treated, apparently inactive 'autoimmune' chronic active hepatitis during withdrawal of maintenance corticosteroid and azathioprine therapy. Reactivation of disease occurred in 26 patients (86%) during or after treatment withdrawal and was as frequent in the Thymostimulin treated (11 of 13; 84%) and untreated (15 of 17; 88%; p>OO5) groups. Reactivation of disease was accompanied by a severe defect in concanavalin A induced suppressor cell activity, the magnitude of which was similar in the Thymostimulin treated and untreated groups (mean % suppression = 16*4 and 3-2 respectively; p>O0O5 vs 84*4 in control subjects). Further studies assessing the optimal dose, duration of treatment, and mode of administration are required to establish a therapeutic role for thymic hormone extracts in 'autoimmune' chronic active hepatitis. 
Chronic active hepatitis of unknown aetiology occurs predominantly in women, often with florid signs of hepatocellular failure, associated autoimmune disease, and marked derangement of liver function. Hyperglobulinaemia primarily involving an increase in immunoglobulin G,1 and the presence of specific2 and non-specific3 autoantibodies are the most striking immunological abnormalities and indicate a disturbance in the immunoregulatory mechanisms controlling antibody production. Antigen specific and non-specific suppressor T lymphocytes are considered to play a major regulatory role in controlling B cell immunoglobulin production4 5 and a defect in suppressor T cell function has been implicated in the pathogenesis of human6 7 (Ausria II and Ausab respectively, Abbott Laboratories, Basingstoke, UK). None had been exposed to known hepatotoxic drugs or transfused with blood or blood products. Duration of disease ranged from three to six years and remission from two to four years as 279 defined by an absence of symptoms, serum aminotransferase (AST) concentrations within the normal range (<40 IU/1) on at least four consecutive six monthly estimations, and liver histology showing mild portal lymphocytic infiltration in the absence of piecemeal necrosis. All patients were receiving prednisolone (5-10 mg) and azathioprine (75-100 mg) daily as maintenance treatment. In two patients on one previous occasion, withdrawal of treatment had resulted in biochemical relapse (AST>240 IU/l) of disease. The study was approved by the ethical committee of King's College Hospital and informed consent was obtained from all subjects.
Thymostimulin was kindly supplied by Serono Laboratories (UK) Ltd, Welwyn Garden City, Herts. The method of extraction and purification has been previously described. 15 Briefly, ammonium acetate extraction of minced calf thymuses is followed by two precipitation steps with ammonium sulphate. The precipitate from the second step is subjected to ultrafiltration and then purified on Sepharose G25 and G50. The resulting extract contains a mixture of polypeptides with molecular weights lower thanl2 000, with two main bands on polyacrylamide gel electrophoresis. Standardisation of the activity of the extract is performed by comparing it with a standard preparation of Thymostimulin in a bioassay using induction of rosette forming cells in guinea pig spleen preparations.16
The patients were randomised to receive intramuscular Thymostimulin 1 mg/kg/day for one week, and 1 mg/kg/week thereafter (13 patients), or no therapy (17 patients) at the beginning of treatment withdrawal. Azathioprine was discontinued and prednisolone simultaneously reduced by 2 mg and by a further 2 mg at two weekly intervals. Serum concentrations of AST, bilirubin, alkaline phosphatase, immunoglobulins, and autoantibody titres were monitored at two weekly intervals. A fourfold rise of AST (>160 IU/l) was taken to indicate reactivation of disease and if this occurred, Thymostimulin was discontinued and treatment recommenced with prednisolone (30 mg) and azathioprine (75 mg).
SUPPRESSOR CELL ASSAY
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The present study confirms previous observations )n accompanied reactivation that reactivation of disease2 accompanied by a s studied, the magnitude of defect in suppressor cell function9 occurs in the the Thymostimulin treated majority of patients with autoimmune chronic active untreated (3.2 ± SD 32-4 hepatitis when maintenance corticosteroid treatment is withdrawn. Thymostimulin, at the dose used, had no effect on the clinical course or on the appearance of the suppressor cell abnormality during treatment withdrawal. Reactivation of -ts induce differentiation of disease occurred as often in the Thymostimulin mus dependent T lympho-treated and untreated groups and was invariably accompanied by a defect in suppressor cell function, the magnitude of which was similar in the two groups. There are a number of possible explanations for this apparent lack of an effect of Thymostimulin in this study. These results represent the first controlled study on the effect of long term parenteral administration of a thymic hormone extract in a well defined, homogenous, carefully monitored patient population. The lack of a demonstrable clinical and immunological effect contrasts with the results of previous in vivo and in vitro studies suggesting that further evaluation is required to assess the effect of different dose schedules, and modes of administration of thymic extracts in patients with chronic active hepatitis.
